Ursodeoxycholic acid — adverse effects and drug interactions

@article{Hempfling2003UrsodeoxycholicA,
  title={Ursodeoxycholic acid — adverse effects and drug interactions},
  author={W. Hempfling and K. Dilger and U. Beuers},
  journal={Alimentary Pharmacology \& Therapeutics},
  year={2003},
  volume={18}
}
Background : Ursodeoxycholic acid is increasingly being used for the treatment of chronic cholestatic liver diseases. It appears to be generally well tolerated, but a systematic review on drug safety is lacking. 
[Ursodeoxycholic acid: A therapeutic niche in an internist's practice].
TLDR
The results of the most important randomized controlled trials determining currently the evidence base for the efficiency and safety of using UDCA in the clinical picture of visceral diseases are given. Expand
Effects of ursodeoxycholic acid on rilpivirine plasma trough concentrations: a case report
TLDR
Co-administration of UDCA resulted in unquantifiable rilpivirine concentrations, but with no effects on darunavir plasma trough concentration, despite the fact that also the latter drug is a substrate of CYP3A enzymes. Expand
Pathogenesis and Treatment of Pruritus in Cholestasis
TLDR
Evidence-based therapeutic recommendations, including the use of anion exchange resins cholestyramine, colestipol and colesevelam, the microsomal enzyme inducer rifampicin, the opioid receptor antagonists naltrexone and naloxone, and the serotonin reuptake inhibitor sertraline, are provided. Expand
Ursodeoxycholic acid in pregnancy ?
TLDR
This Grand Round aims to provide a detailed analysis of the current evidence, safety data and clinical experience with ursodeoxycholic acid (and alternative drugs) during pregnancy and lactation and an advice for clinicians regarding the use of UDCA during pregnancyand lactation is given. Expand
Primary biliary cholangitis: assessment and management strategies
Primary biliary cholangitis (PBC) is an autoimmune disease resulting in permanent damage to the bile ducts in the liver, often leading to symptoms including fatigue and itch that significantly impa...
American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy.
This literature review and the recommendations therein were prepared for the American Gastroenterological Association Institute Clinical Practice and Economics Committee. The paper was approved byExpand
New treatments/targets for primary biliary cholangitis
TLDR
An overview of the current treatment options and future opportunities for patients with primary biliary cholangitis is provided. Expand
Drug-induced diarrhea
TLDR
The mechanism by which drugs induce diarrhea within the broad classification of watery, inflammatory, and fatty characteristics of the stool is examined, which usually includes withdrawal of the offending drug. Expand
Cholestatische Lebererkrankungen und Stoffwechselerkrankungen der Leber
Die cholestatischen und metabolischen Lebererkrankungen stellen neben den nutritiv-toxischen und viralen Hepatopathien die wichtigsten Ursachen fur die Entstehung einer Leberzirrhose dar.
Adherence to ursodeoxycholic acid therapy in patients with cholestatic and autoimmune liver disease.
TLDR
Evaluated adherence to UDCA in relation to patient beliefs about medicine and to identify potential predictors of poor adherence found young age and male sex are associated with poor adherence. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 129 REFERENCES
Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol gallstones: a randomized multicentre trial
Combination therapy using ursodeoxycholic acid plus chenodeoxycholic acid has been advocated for dissolution of cholesterol gallstones because the two bile acids have complementary effects on biliaryExpand
Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.
TLDR
UDCA exerts its beneficial effect in liver diseases through a diverse, probably, complementary array of mechanisms and may have a place in the management of PSC, ICP, cystic fibrosis, PFIC and GVHD involving the liver, although more studies are needed to further determine its therapeutic potential. Expand
Ursodeoxycholic acid in primary biliary cirrhosis.
  • B. Combes
  • Medicine
  • Seminars in liver disease
  • 1997
TLDR
There are favorable trends for ursodiol in preventing transplantation and prolonging survival, but in the absence of randomized, placebo-controlled trials of sufficient duration, there remain impressions rather than statistically proved, strong conclusions. Expand
Ursodeoxycholic acid in cholestasis: Potential mechanisms of action and therapeutic applications
TLDR
Clinical and experimental work that may help to clarify possible mechanisms of action of UDCA in cholestasis and provide a clearer rationale for the administration ofUDCA in special cholESTatic disorders are summarized. Expand
Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin‐clavulanate potassium (Augmentin®)‐induced intra‐hepatic cholestasis: report of two cases
TLDR
It is suggested that ursodeoxycholic acid may be an effective treatment for drug‐associated cholestasis and improvement in patients' hyperbilirubinaemia and symptoms such as pruritus and fatigue. Expand
DETERIORATION OF PRIMARY BILIARY CIRRHOSIS DURING TREATMENT WITH URSODEOXYCHOLIC ACID
TLDR
UDCA was introduced for the dissolution of radiolucent gallstones in the 1970s and is available on prescription in many European countries and now ongoing in Europe and overseas. Expand
Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children.
TLDR
It is demonstrated that long-term UDCA therapy slows the progression of primary biliary cirrhosis and reduces the need for liver transplantation. Expand
Abdominal pain after taking ursodiol.
TLDR
Two patients in whom severe right-upper-quadrant pain developed on repeated occasions within hours after taking ursodiol are reported. Expand
Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases
TLDR
This review outlines the present knowledge of the modes of action of ursodeoxycholic acid, and presents data from clinical trials on its use in chronic liver diseases. Expand
Drug reaction to ursodeoxycholic acid: lichenoid drug eruption in an infant using ursodeoxycholic acid for neonatal hepatitis.
TLDR
This is the first infant case of lichenoid drug eruption associated with ursodeoxycholic acid reported in infants, and the lesions have resolved two months after the discontinuation of the drug. Expand
...
1
2
3
4
5
...